Advertisement


Nathan A. Pennell, MD, PhD, on NSCLC: Lowering Genetic Testing Costs

2018 ASCO Annual Meeting

Advertisement

Nathan A. Pennell, MD, PhD, of the Cleveland Clinic, discusses the economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in newly diagnosed metastatic non–small cell lung cancer (Abstract 9031).



Related Videos

Issues in Oncology
Legislation

Thaddeus Mason Pope, JD, PhD, on Right to Try: Expert Perspective

Thaddeus Mason Pope, JD, PhD, of the Mitchell Hamline School of Law, discusses implications of the federal “Right to Try” law, recently enacted.

Lymphoma

Jeremy S. Abramson, MD, on Non-Hodgkin Lymphoma: Results From the TRANSCEND NHL 001 Trial

Jeremy S. Abramson, MD, of the Massachusetts General Hospital, discusses study findings on lisocabtagene maraleucel in relapsed or refractory aggressive NHL (Abstract 7505).

Gynecologic Cancers

Ursula A. Matulonis, MD, and Daniel J. Margul, MD, PhD, on Cervical Cancer and Minimally Invasive Surgery

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Daniel J. Margul, MD, PhD, of Northwestern University, discuss the outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer (Abstract 5502).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Elizabeth R. Plimack, MD, on RCC: Perspectives on KEYNOTE-427 and IMmotion151

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, offer their analysis of two key studies presented in renal cell cancer.

Lung Cancer

Naoki Furuya, MD, PhD, on NSCLC: Results From the NEJ026 Study

Naoki Furuya, MD, PhD, of the St. Marianna University School of Medicine, discusses phase III study findings on a comparison of bevacizumab plus erlotinib to erlotinib in patients with untreated non–small cell lung cancer with activating EGFR mutations (Abstract 9006).

Advertisement

Advertisement




Advertisement